Blood Test to Predict Cytomegalovirus Flare-Ups in Ulcerative Colitis
Tests a blood test for cytomegalovirus in adults with ulcerative colitis.
Plain-language title generated from the registry record
Registry title: QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis
Key facts
- Where
- Lyon and Saint-Etienne, FranceSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have been infected with cytomegalovirus (CMV) and are in hospital for a flare of ulcerative colitis. It tests whether a blood test can show CMV reactivation in the bowel.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Flare of ulcerative colitis that needs hospital care, with a Mayo score above 5 and an endoscopic subscore of 2 or more.
- Biomarker or test result
- Positive blood test for CMV antibodies (IgG+).
Main reasons for not taking part
- Patients under wardship or curatorship
- Patients who cannot understand or sign the protocol
- Patients who have had a total or partial removal of the colon (colectomy)
Read by machine on 12 November 2026.
Where in France
- HCL - Hôpital Lyon SudLyon, FranceContact: Stéphane NANCEY, MD PhD (principal investigator)Taking people
- CHU Saint-EtienneSaint-Etienne, FranceContact: Xavier ROBLIN, MD PhD (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de Saint Etienne
- Trial code
- NCT04030676
- Record updated
- 29 April 2025
- Original description
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.Read full original descriptionShow less
Place of the QuantiFERON-CMV (QF-CMV) Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis (UC)
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.
Inclusion: Patient with seropositive for CytoMegaloVirus (CMV) (IgG+); Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score > 5 and an endoscopic subscore ≥ 2; Social security affiliation; Signed informed consent.
Exclusion: Wardship patient and curatorial patient; Patient unable to understand or sign the protocol; Colectomy total or partial.